Literature DB >> 2826614

Studies of prototype live hepatitis A virus vaccines in primate models.

R A Karron1, R Daemer, J Ticehurst, E D'Hondt, H Popper, K Mihalik, J Phillips, S Feinstone, R H Purcell.   

Abstract

We have prepared two prototype live hepatitis A virus (HAV) vaccines by serial passage of the HM-175 strain of HAV in African green monkey kidney cells. Passage 21 (P-21) HM-175 virus shows evidence of attenuation for chimpanzees but not for marmosets; passage 32 (P-32) HM-175 virus shows evidence of attenuation for both species. Animals that received P-32 HAV had fewer elevations in levels of liver enzyme activity and evidence of less virus replication in the liver and excretion of virus in stool than did those that received wild-type virus. The P-21 and P-32 viruses were highly immunogenic in both species. The information provided by this study will aid in the development of a live HAV vaccine.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2826614     DOI： 10.1093/infdis/157.2.338

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  16 in total

1.  Identification of VP1/2A and 2C as virulence genes of hepatitis A virus and demonstration of genetic instability of 2C.

Authors:  Suzanne U Emerson; Ying K Huang; Hanh Nguyen; Alicia Brockington; Sugantha Govindarajan; Marisa St Claire; Max Shapiro; Robert H Purcell
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

2.  Mutations responsible for adaptation of hepatitis A virus to efficient growth in cell culture.

Authors:  S U Emerson; C McRill; B Rosenblum; S Feinstone; R H Purcell
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

Review 3.  Clinical development of a new inactivated hepatitis A vaccine.

Authors:  E Vidor; B Fritzell; S Plotkin
Journal:  Infection       Date:  1996 Nov-Dec       Impact factor: 3.553

4.  Attenuation and cell culture adaptation of hepatitis A virus (HAV): a genetic analysis with HAV cDNA.

Authors:  J I Cohen; B Rosenblum; S M Feinstone; J Ticehurst; R H Purcell
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

5.  Progress toward the development of a genetically engineered attenuated hepatitis A virus vaccine.

Authors:  A W Funkhouser; G Raychaudhuri; R H Purcell; S Govindarajan; R Elkins; S U Emerson
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

Review 6.  New hepatitis A vaccines and their role in prevention.

Authors:  D B Strader; L B Seeff
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

7.  Attenuated hepatitis A virus: genetic determinants of adaptation to growth in MRC-5 cells.

Authors:  A W Funkhouser; R H Purcell; E D'Hondt; S U Emerson
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

8.  Chimpanzees as an animal model for human norovirus infection and vaccine development.

Authors:  Karin Bok; Gabriel I Parra; Tanaji Mitra; Eugenio Abente; Charlene K Shaver; Denali Boon; Ronald Engle; Claro Yu; Albert Z Kapikian; Stanislav V Sosnovtsev; Robert H Purcell; Kim Y Green
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

9.  Utilization of chimeras between human (HM-175) and simian (AGM-27) strains of hepatitis A virus to study the molecular basis of virulence.

Authors:  G Raychaudhuri; S Govindarajan; M Shapiro; R H Purcell; S U Emerson
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

10.  cDNA clone of hepatitis A virus encoding a virulent virus: induction of viral hepatitis by direct nucleic acid transfection of marmosets.

Authors:  S U Emerson; M Lewis; S Govindarajan; M Shapiro; T Moskal; R H Purcell
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.